Showing results (2141-2150 of 10,080) with videos related to

Sort By:
Pageof 1,008
Current Pharmaceutical Design|September 15, 2012
The intriguing interplay between therapies targeting the epidermal growth factor receptor, the hypoxic microenvironment and hypoxia-inducible factorsAn Wouters, Carolien Boeckx, Jan B Vermorken, et al.
Current Pharmaceutical Design|July 4, 2012
Non-analgesic effects of opioids: opioid-induced respiratory depressionMerel Boom, Marieke Niesters, Elise Sarton, et al.
Current Pharmaceutical Design|July 4, 2012
Non-analgesic effects of opioids: factors relevant to opioid abuse and abuse- deterrent formulationsJoseph V Pergolizzi, Robert B Raffa, Jason S Pergolizzi, et al.
Current Pharmaceutical Design|July 4, 2012
Non-analgesic effects of opioids: neuroprotection in the retinaShahid Husain, Yasir Abdul, David E Potter
Current Pharmaceutical Design|June 22, 2012
Treatment of cannabis use among people with psychotic disorders: a critical review of randomised controlled trialsAmanda L Baker, Louise K Thornton, Leanne Hides, et al.
Current Pharmaceutical Design|June 22, 2012
Patient's perceptions of the cannabis-psychosis link--a systematic reviewAnna Buadze, Stefan Kaiser, Rudolf Stohler, et al.
Current Pharmaceutical Design|June 22, 2012
Genetic variation underlying psychosis-inducing effects of cannabis: critical review and future directionsJeroen Decoster, Jim van Os, Inez Myin-Germeys, et al.
Current Pharmaceutical Design|June 22, 2012
Resting state abnormalities in psychosis compared to acute cannabinoids and opioids challenges: a systematic review of functional imaging studiesNiklaus Denier, Marc Walter, Kerstin Bendfeldt, et al.
Current Pharmaceutical Design|June 22, 2012
Antipsychotic profile of cannabidiol and rimonabant in an animal model of emotional context processing in schizophreniaRaquel Levin, Valeria Almeida, Fernanda Fiel Peres, et al.
Pageof 1,008